fungal infections in immature newborns have become more common in the previous two decades, especially when they are admitted to a Neonatal Intensive Care Unit (NICU). Thus, it is projected that the mortality rate of children under the age of five is estimated to be about 6 million children a year, with even about 40% of these mortalities during the newborn period. Considering the increased prevalence of death rates related to invasive fungal infections, proper preventative medication is still critical in their treatment. The proper utilization antifungals medicines are critical in the primary prevention and management of invasive fungal infection in newborns; however, there are no specific guidelines to determine the proper medication selection. The most appropriate cure of fungal infection in this population necessitates extensive research into the pharmacokinetic, tolerability, and effectiveness of antifungal medicines. This paper aims to overview epidemiology, diagnosis and management of neonatal fungal infections.Children's invasive fungal infections appear to have become more common during the previous few decades. Children with primary and secondary immunodeficiencies are at danger, as well as newborns. The most often isolated microbes are Candida and Aspergillus species. Improved outcomes depend on prompt diagnosis and administration of the proper antifungal medication. Traditional methods take a lot of time, and obtaining relevant sample material in a paediatric setting may require intrusive procedures. The improvements in detection and quick species identification are summarised in this paper. In light of the antifungal spectrum of the available drugs and the distinct pharmacokinetic features in various age groups, the current antifungal therapy options for newborns and kids are next examined.